- NCIt
- C222490
Loading cancer entity…
Loading cancer entity…
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07698535 | Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial | recruiting | Phase 2 | 64 | University of WashingtonOTHER | 1 | Aug 27, 2026 |
| clinicaltrials |
| NCT07219147 | 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 22 | Calibr, a division of Scripps ResearchOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials